# A Study to Evaluate the Safety, Immunogenicity and Efficacy of GlaxoSmithKline (GSK) Biologicals' Candidate Malaria Vaccine RTS,S/AS02A, When Administered to Children Aged 1 to 4 Years Living in a Malaria-endemic Region of Mozambique.

> **NCT00197041** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 2022 (actual)

## Conditions studied

- Malaria

## Interventions

- **BIOLOGICAL:** RTS,S/AS02A

## Key facts

- **NCT ID:** NCT00197041
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-07
- **Primary completion:** 2005-04
- **Final completion:** 2005-04
- **Target enrollment:** 2022 (ACTUAL)
- **Last updated:** 2016-09-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00197041

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00197041, "A Study to Evaluate the Safety, Immunogenicity and Efficacy of GlaxoSmithKline (GSK) Biologicals' Candidate Malaria Vaccine RTS,S/AS02A, When Administered to Children Aged 1 to 4 Years Living in a Malaria-endemic Region of Mozambique.". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00197041. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*